Lubin Arevalo Santana, MD
Gastroenterology · Miami, FLNPI 1942533997
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,406 of the $21,648 with a category attached, or 71.2%. 25 manufacturers reported payments, led by Sanofi at 50.5% of the total. 2025 is the largest year on record at $15,585, more than ten times the $199 reported in 2019. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $270.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$11K
- Laborie Medical Technologies Corp.$4K
- Medtronic$2K
- Ardelyx, Inc.$2K
- Enterra Medical, Inc.$1K
- Olympus Corporation Of The Americas$749
- plus $2K from 19 others
Across 2 payments — averaging $523.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$546
- Takeda Pharmaceuticals U.S.A., Inc.$500
What the payments were for
- Consulting fees$15,40671%
- Travel & lodging$2,31911%
- Food & beverage$3,73517%
- Education$1891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $10,925 |
| Laborie Medical Technologies Corp. | 1 | $3,825 |
| Medtronic | 15 | $1,677 |
| Ardelyx, Inc. | 2 | $1,583 |
| Enterra Medical, Inc. | 5 | $1,270 |
| Olympus Corporation Of The Americas | 6 | $749 |
| Johnson & Johnson(2 entities) | 8 | $336 |
| AbbVie(2 entities) | 11 | $315 |
| Pentax Of America, Inc. | 3 | $167 |
| Madrigal Pharmaceuticals | 1 | $146 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| QOL Medical, LLC | 6 | $87 |
| Davol Inc. | 1 | $69 |
| Endogastric Solutions, Inc | 1 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Celltrion USA Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Apollo Endosurgery US Inc | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,648 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 94 | $83,808 |
| MotegrityPrucalopride Succinate | 22 | $16,486 |
| TrulancePlecanatide | 15 | $11,414 |
| Sucralfate | 37 | $2,961 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 14 | $2,401 |
| Mesalamine | 11 | $2,324 |
| Famotidine | 89 | $1,493 |
| Pantoprazole Sodium | 124 | $1,211 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 12 | $743 |
| Rabeprazole Sodium | 22 | $722 |
| Omeprazole | 44 | $600 |
| Esomeprazole Magnesium | 17 | $491 |
| Ondansetron Hcl | 16 | $169 |
| Hydrocortisone | 13 | $161 |
| Dicyclomine Hcl | 11 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $315 | $83,80894 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $25 | $16,48622 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $32 | $11,41415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Miami
- Lukasz KwapiszMiami$1.2M
- Joanna LopezMiami$670K
- Jerry MartelMiami$511K
- Andres GelrudMiami$208K
- Maria HernandezMiami$197K
- George SanchezMiami$117K
- Jodie BarkinMiami$101K
- Javier ParraMiami$68K
- Samuel GidayOrlando$2M
- Jennifer Seminerio-DiehlOrlando$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.